Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.38Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 68.94%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical achievements, particularly with the promising LOTIS-7 trial data, and demonstrated effective cost management and revenue stability. However, the discontinuation of the ADCT602 trial and a notable net loss are concerning. Despite these challenges, the company's financial outlook remains strong with a solid cash runway.Company Guidance
During ADC Therapeutics' First Quarter 2025 Earnings Call, the company provided guidance on several key metrics. The first quarter revenues totaled $23 million, with net product revenues from ZYNLONTA amounting to $17.4 million, aligning with first quarter sales in 2024 and showing improvement over $16.4 million in the fourth quarter of 2024. Milestone and royalty payments contributed an additional $5.6 million to the total revenue. ADC Therapeutics reported a net loss of $38.6 million, or $0.36 per share, compared to a net loss of $46.6 million, or $0.56 per share, in the same period of 2024, primarily due to increased licensing revenues and reduced expenses. The company maintains a cash runway expected to fund operations into the second half of 2026, with cash and cash equivalents at $194.7 million as of March 31, 2025. The guidance highlighted the promising data from their LOTIS-7 trial, showing a 95.5% overall response rate and a 90.9% complete response rate, and plans to expand patient enrollment to support regulatory discussions. The Phase 3 LOTIS-5 trial continues to progress, with expectations to reach the pre-specified number of progression-free survival events by the end of 2025.Promising LOTIS-7 EHA Abstract Data
ZYNLONTA plus glofitamab demonstrated an overall response rate of 95.5% and a complete response rate of 90.9% in 22 efficacy-evaluable patients, significantly higher than typical rates in other bispecific combination trials.
Financial Performance
Total first quarter revenues were $23 million, including net product revenues of $17.4 million and an additional $5.6 million from milestone and royalty payments.
Cost Management
Total operating expenses for the first quarter were $49.1 million on a non-GAAP basis, representing a 5% net decrease over the prior year, driven primarily by a reduction in SG&A.
Cash Runway
Cash and cash equivalents were $194.7 million as of March 31, 2025, with a runway expected to fund operations into the second half of 2026.
ADCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.32 | $1.81 | +37.12% |
Mar 27, 2025 | $1.58 | $1.52 | -3.80% |
Nov 07, 2024 | $3.20 | $2.93 | -8.44% |
Aug 06, 2024 | $2.87 | $2.92 | +1.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ADC Therapeutics Ltd (ADCT) report earnings?
ADC Therapeutics Ltd (ADCT) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is ADC Therapeutics Ltd (ADCT) earnings time?
ADC Therapeutics Ltd (ADCT) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADCT EPS forecast?
ADCT EPS forecast for the fiscal quarter 2025 (Q2) is -0.4.